Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call

Rhea-AI Summary

Celcuity Inc. (NASDAQ:CELC) will announce its Q1 2022 financial results on May 16, 2022, post-market close. A webcast and conference call are scheduled for the same day at 4:30 p.m. ET to discuss results and corporate updates. The company is focused on an integrated therapeutic and companion diagnostic strategy for cancer treatment. Its lead drug, gedatolisib, is a dual inhibitor targeting PI3K and mTOR, with a Phase 3 study expected to begin in 2022 for HR+/HER2- advanced breast cancer. More details can be found on its website.

Positive

• Upcoming Q1 2022 financial results announcement may provide insights into company performance.
• Initiation of Phase 3 study for gedatolisib in HR+/HER2- advanced breast cancer in 2022.

Negative

• None.

MINNEAPOLIS, MN / ACCESSWIRE / May 9, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that it will release its financial results for the first quarter 2022 after the stock market close on Monday, May 16, 2022. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Webcast and Conference Call Information

To participate in the teleconference, domestic callers should dial 1-844-825-9789 and international callers should dial 1-412-317-5180 and reference conference ID: 10166506. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1545538&tp_key=5a345444e1. A replay of the webcast will be available on the Celcuity website following the live event.

About Celcuity

Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The company's lead therapeutic candidate is gedatolisib, a potent, reversible dual inhibitor that selectively targets all Class I isoforms of PI3K and mTOR. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. The company expects to initiate a Phase 3 study evaluating gedatolisib in patients with HR+/HER2- advanced breast cancer in 2022. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com.

Contacts:

Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
763-392-0123

ICR Westwicke
Robert Uhl, robert.uhl@westwicke.com
(619) 228-5886

SOURCE: Celcuity Inc.

View source version on accesswire.com:
https://www.accesswire.com/700586/Celcuity-Inc-Schedules-Release-of-First-Quarter-2022-Financial-Results-and-WebcastConference-Call

FAQ

When will Celcuity release its Q1 2022 financial results?

Celcuity will release its Q1 2022 financial results on May 16, 2022, after the market close.

What is the significance of the gedatolisib drug by Celcuity?

Gedatolisib is a dual inhibitor targeting PI3K and mTOR, with potential benefits for patients with HR+/HER2- advanced breast cancer.

How can I participate in the Celcuity Q1 2022 financial results call?

To participate, domestic callers can dial 1-844-825-9789, while international callers should dial 1-412-317-5180, referencing conference ID: 10166506.

What is the CELsignia companion diagnostic platform?

CELsignia is Celcuity's diagnostic platform that analyzes live patient tumor cells to identify cancer patients likely to benefit from approved targeted therapies.